Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christos Chouaid

Showing results (141-150 of 210) with videos related to

Pageof 21
Sort By:
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|October 9, 2025
The Geographical Deprivation Index is Independently Associated With All-Cause Long-Term Mortality in Resectable Lung CancerMatteo Petroncini, Alexandra Lucien, Lorenzo Gherzi, et al.
Targeted Oncology|May 24, 2019
Real-Life Efficacy of Osimertinib in Pretreated Octogenarian Patients with T790M-Mutated Advanced Non-small Cell Lung CancerJean-Bernard Auliac, Karima Saboundji, Michel Andre, et al.
Journal of Thoracic Disease|December 23, 2017
Prognostic role of a comprehensive geriatric assessment on the management of elderly patients with advanced non-small cell lung cancer (NSCLC): a pooled analysis of two prospective phase II trials by the GFPC GroupHervé Le Caer, Isabelle Borget, Romain Corre, et al.
ERJ Open Research|April 26, 2018
Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancerAdrien Costantini, Jennifer Corny, Vincent Fallet, et al.
Cancer Medicine|May 16, 2020
Duration of nivolumab for pretreated, advanced non-small-cell lung cancerMargaux Geier, Renaud Descourt, Romain Corre, et al.
Lung Cancer (Amsterdam, Netherlands)|September 7, 2019
Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study)Renaud Descourt, Maurice Perol, Gaëlle Rousseau-Bussac, et al.
Cancer Research Communications|July 14, 2026
Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non-Small Cell Lung Cancer: Insights From the EVOKE-01 StudyEnriqueta Felip, Peiwen Kuo, Pilar Garrido, et al.
BMC Cancer|December 21, 2019
Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancerManon Kissel, Isabelle Martel-Lafay, Justine Lequesne, et al.
Interactive Cardiovascular and Thoracic Surgery|March 14, 2015
A randomized trial comparing adjuvant chemotherapy with gemcitabine plus cisplatin with docetaxel plus cisplatin in patients with completely resected non-small-cell lung cancer with quality of life as the primary objectiveFabrice Barlesi, Christos Chouaid, Jacky Crequit, et al.
Lung Cancer (Amsterdam, Netherlands)|January 22, 2016
A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung CancerGerald Schmid-Bindert, Walburga Engel-Riedel, Martin Reck, et al.
Pageof 21

Showing results (141-150 of 210) with videos related to

Sort By:
Pageof 21
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|October 9, 2025
The Geographical Deprivation Index is Independently Associated With All-Cause Long-Term Mortality in Resectable Lung CancerMatteo Petroncini, Alexandra Lucien, Lorenzo Gherzi, et al.
Targeted Oncology|May 24, 2019
Real-Life Efficacy of Osimertinib in Pretreated Octogenarian Patients with T790M-Mutated Advanced Non-small Cell Lung CancerJean-Bernard Auliac, Karima Saboundji, Michel Andre, et al.
Journal of Thoracic Disease|December 23, 2017
Prognostic role of a comprehensive geriatric assessment on the management of elderly patients with advanced non-small cell lung cancer (NSCLC): a pooled analysis of two prospective phase II trials by the GFPC GroupHervé Le Caer, Isabelle Borget, Romain Corre, et al.
ERJ Open Research|April 26, 2018
Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancerAdrien Costantini, Jennifer Corny, Vincent Fallet, et al.
Cancer Medicine|May 16, 2020
Duration of nivolumab for pretreated, advanced non-small-cell lung cancerMargaux Geier, Renaud Descourt, Romain Corre, et al.
Lung Cancer (Amsterdam, Netherlands)|September 7, 2019
Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study)Renaud Descourt, Maurice Perol, Gaëlle Rousseau-Bussac, et al.
Cancer Research Communications|July 14, 2026
Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non-Small Cell Lung Cancer: Insights From the EVOKE-01 StudyEnriqueta Felip, Peiwen Kuo, Pilar Garrido, et al.
BMC Cancer|December 21, 2019
Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancerManon Kissel, Isabelle Martel-Lafay, Justine Lequesne, et al.
Interactive Cardiovascular and Thoracic Surgery|March 14, 2015
A randomized trial comparing adjuvant chemotherapy with gemcitabine plus cisplatin with docetaxel plus cisplatin in patients with completely resected non-small-cell lung cancer with quality of life as the primary objectiveFabrice Barlesi, Christos Chouaid, Jacky Crequit, et al.
Lung Cancer (Amsterdam, Netherlands)|January 22, 2016
A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung CancerGerald Schmid-Bindert, Walburga Engel-Riedel, Martin Reck, et al.
Pageof 21